ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Phase 1 Study Asked to Determine If Drug Administration Timing Improves Results

April 4, 1986

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

ORI Final Findings Of Scientific Misconduct

September 16, 1994

Bevacizumab Prolongs Survival In Patients With Advanced Colorectal Cancer

November 26, 2004

Program Announcement In Preventative Oncology

May 21, 1982

Clinton Declares Month of April Cancer Control Month

April 11, 1997